Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.
In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...
Dr Philip Mease shares his clinical insights for diagnosing and treating fibromyalgia and psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results